FDA Guideline: Post-Marketing Commitments, Risk Evaluation & Mitigation Strategies (REMS)
Harmonising US REMS and EU or UK risk minimisation measures where possible
Harmonising US REMS and EU or UK Risk Minimisation Measures Where Possible In both the US and EU regulatory environments, risk management is a critical component of pharmaceutical product lifecycle management. In the United States, this is managed through Risk Evaluation and Mitigation Strategies (REMS) as outlined in Title 21 of the Code of Federal Regulations (CFR) § 229. In the European Union and the United Kingdom, similar objectives are achieved through Risk Minimisation Measures (RMMs). Understanding and harmonising these approaches is increasingly important for pharmaceutical professionals working across multiple regions. This guide will delineate the similarities and differences between…
Communication strategies to explain REMS to HCPs and patients
Effective Communication Strategies for Explaining REMS to Healthcare Professionals and Patients The Risk Evaluation and Mitigation Strategy (REMS) is a critical component in the post-marketing commitments established by the U.S. Food and Drug Administration (FDA). It aims to ensure that the benefits of certain medications outweigh their risks, particularly when these risks are substantial. For pharmaceutical companies, mastering communication around REMS is essential for compliance and safeguarding public health. This tutorial outlines a structured approach for healthcare professionals (HCPs) and patients, helping regulatory affairs teams, medical affairs professionals, and clinical operations personnel convey REMS effectively. Understanding REMS and Its Regulatory…
Future trends in REMS simplification and digital enablement
Future Trends in REMS Simplification and Digital Enablement Risk Evaluation and Mitigation Strategies (REMS) have become an essential component of the U.S. Food and Drug Administration’s (FDA) approach to ensuring that the benefits of certain drugs outweigh their risks. As pharmaceutical innovation accelerates, the complexities surrounding the post-marketing commitments (PMCs) tied to REMS programs are evolving. This comprehensive guide discusses future trends in REMS simplification and digital enablement, catering to professionals in clinical operations, regulatory affairs, and medical affairs in the U.S., U.K., and EU markets. Understanding REMS and Its Importance REMS were established under the Food and Drug Administration…
Regulatory consequences of missed or delayed REMS and PMR milestones
Understanding the Regulatory Consequences of Missed or Delayed REMS and PMR Milestones The pharmaceutical landscape is marked by stringent regulatory requirements, particularly when it comes to post-marketing commitments (PMCs) and Risk Evaluation and Mitigation Strategies (REMS). Both REMS and post-marketing requirements (PMRs) play a crucial role in ensuring drug safety and efficacy, but what are the regulatory consequences if milestones related to these commitments are missed or delayed? This tutorial provides a comprehensive step-by-step overview specifically designed for pharma professionals involved in clinical operations, regulatory affairs, and medical affairs in the United States, United Kingdom, and European Union. 1. Introduction…
KPIs to measure success and burden of REMS and PMR activities
KPIs to Measure Success and Burden of REMS and PMR Activities KPI Measurement for REMS and PMR Activities: A Regulatory Compliance Guide Pharmaceutical companies are increasingly faced with the challenge of demonstrating the effectiveness and burden of Risk Evaluation and Mitigation Strategies (REMS) and Post-Marketing Commitments (PMCs). These programs are critical for ensuring patient safety and therapeutic efficacy, especially when a drug’s risk profile necessitates additional oversight after it has entered the market. A systematic approach to measuring Key Performance Indicators (KPIs) for REMS and PMR activities is essential for regulatory compliance and optimisation. Understanding REMS and PMR: Definitions and…
Third party vendor management for REMS hubs and service providers
Third Party Vendor Management for REMS Hubs and Service Providers Third Party Vendor Management for REMS Hubs and Service Providers In the landscape of pharmaceutical regulation, particularly with regard to post-marketing commitments (PMCs), the management of third-party vendors playing a role in Risk Evaluation and Mitigation Strategies (REMS) is crucial. This guide aims to provide pharmaceutical professionals with a comprehensive step-by-step tutorial on effective third-party vendor management for REMS hubs and service providers, highlighting regulatory expectations from the US FDA. Understanding REMS and Its Importance Risk Evaluation and Mitigation Strategies (REMS) are critical tools used by the FDA to ensure…
Budgeting and resource planning for complex REMS implementation
Budgeting and Resource Planning for Complex REMS Implementation The Risk Evaluation and Mitigation Strategies (REMS) framework established by the U.S. Food and Drug Administration (FDA) plays a critical role in ensuring that the benefits of a drug outweigh its risks. This article serves as a comprehensive tutorial for pharmaceutical professionals involved in the budgeting and resource planning necessary for successful REMS implementation. With a focus on US regulations and comparative insights from the UK and EU, we explore the intricacies of complying with post-marketing commitments (PMCs) and post-marketing requirements (PMRs). Understanding the Basics of REMS REMS are risk management plans…
Technology platforms to manage enrolment, training and REMS reporting
Technology platforms to manage enrolment, training and REMS reporting Utilizing Technology Platforms to Enhance Enrolment, Training, and REMS Reporting The management of post-marketing commitments (PMCs) and post-marketing requirements (PMRs) is crucial for ensuring compliance with regulatory expectations. One area that requires particular attention is the Risk Evaluation and Mitigation Strategies (REMS) program implemented by the US FDA. To effectively manage these obligations, numerous technology platforms have emerged, providing pharmaceutical companies with tools for enrolment, training, and reporting. This article will guide professionals in leveraging these technological solutions in compliance with FDA regulations. Understanding REMS: A Regulatory Framework REMS are essential…
Audit and inspection focus areas for REMS and post marketing commitments
Audit and Inspection Focus Areas for REMS and Post Marketing Commitments The implementation of post marketing commitments (PMCs) and risk evaluation and mitigation strategies (REMS) plays a pivotal role in ensuring the safe use of pharmaceutical products after they reach the market. Regulatory authorities, particularly the US Food and Drug Administration (FDA), conduct audits and inspections to assess compliance with the mandates associated with these strategies. Understanding the focus areas for these audits and inspections is critical for pharmaceutical professionals engaged in clinical operations, regulatory affairs, and medical affairs. This tutorial provides a comprehensive step-by-step guide to help professionals navigate…
Post marketing commitments and requirements PMCs and PMRs explained for pharma
Post marketing commitments and requirements PMCs and PMRs explained for pharma Understanding Post Marketing Commitments (PMCs) and Post Marketing Requirements (PMRs) in the Pharmaceutical Industry Introduction to Post Marketing Commitments and Requirements The approval of a new drug by the US Food and Drug Administration (FDA) marks a significant milestone in its development lifecycle; however, it also triggers a series of ongoing responsibilities known as post marketing commitments (PMCs) and post marketing requirements (PMRs). Both PMCs and PMRs are crucial for ensuring that a medication is safe and effective within the population it serves. Understanding their distinctions and implications is…